Pazopanib is a potent and selective multitargeted receptor tyrosine kinase inhibitor that showed efficacy in a phase III trial in STS, and it is currently approved for the treatment of advanced STS (except LPS) pretreated with anthracyclines [47, 48]. The gene discussed is NTRK1; the disease is telomere syndrome.